https://www.diabesityrounds.com 2026-10-25T02:03:07.359592+00:00 hourly 1 https://www.diabesityrounds.com/topics 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/hubs 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/archive 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/about 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/editorial-policy 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/corrections 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/disclosures 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/subscribe 2026-10-25T04:22:21.059Z https://www.diabesityrounds.com/topics/incretins 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/obesity 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/type-2-diabetes 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/type-1-diabetes 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/technology 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/cardiorenal 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/masld 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/surgery 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/prevention 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/nutrition 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/pregnancy 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/children 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/topics/regulatory 2026-10-25T04:22:21.059Z daily https://www.diabesityrounds.com/hubs/bariatric-surgery 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/cgm 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/masld 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/metformin 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/weekly-insulins 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/oral-semaglutide 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/orforglipron 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/retatrutide 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/semaglutide 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/sglt2-inhibitors 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/hubs/tirzepatide 2026-10-10T05:12:34.85423+00:00 daily https://www.diabesityrounds.com/a/oral-glp-1-agonists-early-hba1c-data-regulators-acting-safety-data-still-missing 2026-10-25T02:03:07.359592+00:00 https://www.diabesityrounds.com/a/fda-approves-once-weekly-insulin-awiqli-for-children-with-type-2-diabetes 2026-10-23T20:32:11.115975+00:00 https://www.diabesityrounds.com/a/retatrutide-cut-sleep-apnoea-severity-more-than-placebo-in-two-phase-3-trials 2026-10-23T20:17:48.717853+00:00 https://www.diabesityrounds.com/a/cdsco-expert-committee-trial-permission-recommended-for-oral-semaglutide-3-more 2026-10-23T20:02:00.346224+00:00 https://www.diabesityrounds.com/a/diabetes-duration-and-insulin-use-predicted-remission-in-armms-t2d 2026-10-21T20:32:29.269012+00:00 https://www.diabesityrounds.com/a/semaglutide-safety-by-egfr-in-flow-fewer-serious-adverse-events-than-placebo 2026-10-21T20:17:35.649639+00:00 https://www.diabesityrounds.com/a/cdsco-expert-committee-virchow-liraglutide-and-roche-petrelintide-trials 2026-10-21T20:01:55.786106+00:00 https://www.diabesityrounds.com/a/degludec-linked-to-lower-all-cause-mortality-than-glargine-in-swedish-register 2026-10-20T20:47:21.196851+00:00 https://www.diabesityrounds.com/a/fda-flags-most-serious-recall-of-nova-statstrip-gen-2-0-hospital-glucose-meters 2026-10-20T20:32:17.430902+00:00 https://www.diabesityrounds.com/a/carotid-plaque-linked-to-later-cardiovascular-events-in-adults-with-type-1-diabe 2026-10-20T20:17:17.987145+00:00 https://www.diabesityrounds.com/a/smart-mdi-non-inferior-to-mdi-plus-cgm-in-type-1-diabetes-with-hba1c-of-8-or-mor 2026-10-20T20:02:18.812562+00:00 https://www.diabesityrounds.com/a/oral-glp-1-drugs-a-committee-opinion-registry-numbers-and-an-early-phase-ii-sign 2026-10-18T05:26:54.051236+00:00 https://www.diabesityrounds.com/a/oral-glp-1-agonist-hrs-7535-lowered-hba1c-in-phase-ii-trial-in-type-2-diabetes 2026-10-18T05:01:02.722022+00:00 https://www.diabesityrounds.com/a/cgm-lowers-hba1c-in-adults-with-type-2-diabetes-not-using-insulin-in-primary-car 2026-10-18T04:45:42.884633+00:00 https://www.diabesityrounds.com/a/ema-committee-backs-orforglipron-foundayo-for-weight-management-and-type-2-diabe 2026-10-18T04:30:41.901723+00:00 https://www.diabesityrounds.com/a/oral-orforglipron-vs-dapagliflozin-on-metformin-achieve-2-hba1c-results-posted 2026-10-18T04:15:55.698835+00:00 https://www.diabesityrounds.com/a/type-1-diabetes-linked-to-higher-mortality-with-a-larger-relative-gap-in-females 2026-10-15T20:17:09.874016+00:00 https://www.diabesityrounds.com/a/indian-moderate-carbohydrate-diet-plus-exercise-60-9-estimated-remission-in-earl 2026-10-15T20:02:19.506512+00:00 https://www.diabesityrounds.com/a/cdsco-expert-committee-no-phase-iii-waiver-for-alkem-semaglutide 2026-10-15T02:20:21.652324+00:00 https://www.diabesityrounds.com/a/tirzepatide-lowered-hscrp-and-nt-probnp-in-a-meta-analysis-of-seven-studies 2026-10-14T20:03:59.849207+00:00 https://www.diabesityrounds.com/a/network-meta-analysis-sglt2-inhibitors-versus-finerenone-in-ckd-with-type-2-diab 2026-10-13T20:03:56.190691+00:00 https://www.diabesityrounds.com/a/meta-analysis-sglt2-inhibitors-reduce-heart-failure-or-cv-death-in-type-2-diabet 2026-10-13T20:02:18.237942+00:00 https://www.diabesityrounds.com/a/the-next-wave-of-glp-1-drugs-early-promise-but-cost-and-access-still-unclear 2026-10-11T14:01:46.477605+00:00 https://www.diabesityrounds.com/a/orforglipron-with-insulin-glargine-larger-hba1c-fall-than-placebo-in-phase-3 2026-10-11T13:52:31.654737+00:00 https://www.diabesityrounds.com/a/twiist-automated-insulin-delivery-in-type-2-diabetes-13-week-single-arm-trial 2026-10-11T13:53:15.727713+00:00 https://www.diabesityrounds.com/a/semaglutide-in-diabetic-kidney-disease-primary-mri-outcomes-not-met-in-52-week-t 2026-10-10T05:36:22.551567+00:00 https://www.diabesityrounds.com/a/ada-and-easd-2026-consensus-earlier-sglt2-inhibitor-or-glp-1-use-in-type-2-diabe 2026-10-11T14:03:35.931756+00:00 https://www.diabesityrounds.com/a/resmetirom-effects-in-mash-were-similar-across-common-risk-genotypes 2026-10-11T13:57:43.579911+00:00 https://www.diabesityrounds.com/a/oral-safiglipron-versus-dapagliflozin-in-type-2-diabetes-phase-3-trial-in-china 2026-10-11T13:58:23.952713+00:00 https://www.diabesityrounds.com/a/chemically-synthesised-semaglutide-hd1916-matches-wegovy-for-weight-loss-in-chin 2026-10-11T14:04:21.413882+00:00 https://www.diabesityrounds.com/a/nearly-one-in-four-indigenous-adults-in-odisha-had-impaired-kidney-function-in-a 2026-10-11T13:59:49.276317+00:00 https://www.diabesityrounds.com/a/triple-agonist-ubt251-lowered-body-weight-over-24-weeks-in-a-phase-2-trial 2026-10-11T13:47:40.772746+00:00